Thrombocytopenia and Mexiletine

Letters and Corrections1 January 1984Thrombocytopenia and MexiletineGIAN PIERO FASOLA, M.D., FRANCESCO D'OSUALDO, M.D., VINCENZO DE PANGHER, M.D., ENZO BARDUCCI, M.D.GIAN PIERO FASOLA, M.D.Search for more papers by this author, FRANCESCO D'OSUALDO, M.D.Search for more papers by this author, VINCENZO DE PANGHER, M.D.Search for more papers by this author, ENZO BARDUCCI, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-100-1-162_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Mexiletine, a primary amine that resembles lidocaine in chemical structure, is a new anti-arrhythmic agent without known haematologic side effects. Adverse reactions to the drug include only one case of thrombocytopenia (1). We report the case of a patient who developed thrombocytopenia after mexiletine administration.On 18 June 1983, a 53-year-old man was hospitalized with heart failure and ischemic heart disease. Two platelet counts obtained 2 weeks and a few days before admission were normal (greater than 200 000/mm3). There was no history of drug allergy or thrombocytopenia, and no evidence of splenomegaly. Body temperature, erythrocyte sedimentation...References1. CAMPBELL N, PANTRIDGE J, and ADGEY A. Long-term oral antiarrhythmic therapy with mexiletine. Br Heart J. 1978;40:796-801. CrossrefMedlineGoogle Scholar2. GARG S, AMAROSI E, and KARPATKIN S. Use of the megathrombocyte as an index of megakaryocyte number. Ann Intern Med. 1972;77:361-4. LinkGoogle Scholar3. HOIGNÉ R. Drug induced immune-thrombocytopenia. Acta Haematol. 1982;68:1-2. CrossrefMedlineGoogle Scholar4. GYNN T, MESSMORE H, and FRIEDMAN I. Drug-induced thrombocytopenia. Med Clin North Am. 1972;56:65-79. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: GIAN PIERO FASOLA, M.D.; FRANCESCO D'OSUALDO, M.D.; VINCENZO DE PANGHER, M.D.; ENZO BARDUCCI, M.D.Affiliations: Monfalcone General Hospital 34074 Monfalcone Italy PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAnti-arrhythmic medications increase non-cardiac mortality – A meta-analysis of randomized control trialsMexiletineClinical Pharmacology of Antiarrhythmic DrugsANTIDYSRHYTHMIC DRUGSMexiletineAnalytical Profile of Mexiletine HydrochloridePoisoning Due to Class 1B Antiarrhythmic DrugsMexiletineMexiletine for the Management of Ventricular Arrhythmias in Ischemic Heart DiseaseMexiletine: Its Role in the Management of Chronic Ventricular ArrhythmiasPseudothrombocytopenia: a cold autoantibody against platelet glycoprotein GP II bPharmacology and Clinical Use of MexiletineCardiac glycosides and drugs used in dysrhythmiasCardiac glycosides and drugs used in dysrhythmiasPseudothrombocytopenia and MexiletineGERD GIRMANN, M.D., HANS PEES, M.D., PAUL GERHARD SCHEURLEN, M.D. 1 January 1984Volume 100, Issue 1Page: 162-162KeywordsAdverse reactionsAllergy and immunologyCardiovascular therapyDrugsHeart failurePlateletsSplenomegalyTemperature ePublished: 1 December 2008 Issue Published: 1 January 1984 PDF downloadLoading ...